Product Description
ION464, also known as BIIB101, is an investigational antisense medicine designed to inhibit the production of the alpha-synuclein protein as a potential therapy for Parkinson's disease (PD), multiple system atrophy (MSA) and related synucleinopathies. (Sourced from: https://www.ionispharma.com/medicines/ionis-biib6/)
Mechanisms of Action: aSYN Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ionis
Company Location: Western America
Company Founding Year: 1989
Additional Commercial Interests: Biogen
Clinical Description
Countries in Clinic: Austria, France, Germany, Portugal, United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple System Atrophy|Shy-Drager Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04165486 |
HORIZON | P1 |
Recruiting |
Multiple System Atrophy|Shy-Drager Syndrome |
2027-09-01 |
50% |
2024-01-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/13/2025 |
News Article |
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum |
|
01/13/2021 |
News Article |
Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade |